Chengcheng Hu

Chengcheng Hu

Director, Biostatistics - Phoenix Campus
Professor, Public Health
Professor, Statistics-GIDP
Professor, BIO5 Institute
Primary Department
Department Affiliations
Contact
(520) 626-9308

Work Summary

Chengcheng Hu has worked on a broad range of areas including cancer, occupational health, HIV/AIDS, and aging. He has extensive collaborative research in conducting methodological research in the areas of survival analysis, longitudinal data, high-dimensional data, and measurement error. His current methodological interest, arising from studies of viral and human genetics and biomarkers, is to develop innovative methods to investigate the relationship between high-dimensional information and longitudinal outcomes or survival endpoints.

Research Interest

Chengcheng Hu, Ph.D., is an Associate Professor, Public Health and Director, Biostatistics, Phoenix campus at the Mel and Enid Zuckerman College of Public Health, University of Arizona. He is also Director of the Biometry Core on the Chemoprevention of Skin Cancer Project at the University of Arizona Cancer Center. Hu has worked on multiple federal grants in a broad range of areas including cancer, occupational health, HIV/AIDS, and aging. In addition to extensive experience in collaborative research, he has conducted methodological research in the areas of survival analysis, longitudinal data, high-dimensional data, and measurement error. His current methodological interest, arising from studies of viral and human genetics and biomarkers, is to develop innovative methods to investigate the relationship between high-dimensional information and longitudinal outcomes or survival endpoints. Hu joined the UA Mel and Enid Zuckerman College of Public Health in 2008. Prior to this he was an assistant professor of Biostatistics at the Harvard School of Public Health from 2002 to 2008. While at Harvard, he also served as senior statistician in the Pediatric AIDS Clinical Trials Group (PACTG) and the International Maternal Pediatric Adolescent AIDS Clinical Trials Group (IMPAACT). Hu received his Ph.D. and M.S. in Biostatistics from the University of Washington and a M.A. in Mathematics from the Johns Hopkins University.

Publications

Yanez, N. D., Aljasser, I., Andre, M., Hu, C., Juraska, M., & Lumley, T. (2017). Assessing the impact of measurement error in modeling change in the absence of auxiliary data. COMMUNICATIONS IN STATISTICS-THEORY AND METHODS, 46(6), 2667-2680.
Chen, Z., Klimentidis, Y. C., Bea, J. W., Ernst, K. C., Hu, C., Jackson, R., & Thomson, C. A. (2017). Body Mass Index, Waist Circumference, and Mortality in a Large Multiethnic Postmenopausal Cohort-Results from the Women's Health Initiative. Journal of the American Geriatrics Society, 65(9), 1907-1915.

To determine whether the relationship between anthropometric measurements of obesity and mortality varies according to age, race, and ethnicity in older women.

Garvie, P. A., Flynn, P. M., Belzer, M., Britto, P., Hu, C., Graham, B., Neely, M., McSherry, G. D., Spector, S. A., Gaur, A. H., & , P. A. (2011). Psychological factors, beliefs about medication, and adherence of youth with human immunodeficiency virus in a multisite directly observed therapy pilot study. The Journal of adolescent health : official publication of the Society for Adolescent Medicine, 48(6), 637-40.

This study examined psychological functioning and beliefs about medicine in adolescents with human immunodeficiency virus (HIV) on highly active antiretroviral therapy in a community-based directly observed therapy (DOT) pilot feasibility study. Participants were youth with behaviorally acquired HIV (n = 20; 65% female; median age, 21 years) with adherence problems, who received once-daily DOT. Youth were assessed at baseline, week 12 (post-DOT), and week 24 (follow-up). At baseline, 55% of youth reported having clinical depressive symptoms compared to 27% at week 12 with sustained improvements at week 24. At baseline, substance use was reported within the borderline clinical range (T(score) = 68), with clinical but statistically nonsignificant improvement (T(score) = 61) at week 12. Hopelessness scores reflected optimism for the future. Coping strategies showed significantly decreased cognitive avoidance (p = .02), emotional discharge (p = .004), and acceptance/resignation ("nothing I can do," p = .004), whereas positive reappraisal and seeking support emerged. With the exception of depressive symptoms, week 12 improvements were not sustained at week 24. DOT adherence was predicted by higher baseline depression (p = .05), beliefs about medicine (p = .006) and perceived threat of illness scores (p = .03). Youth with behaviorally acquired HIV and adherence problems who participated in a community-based DOT intervention reported clinically improved depressive symptoms, and temporarily reduced substance use and negative coping strategies. Depressive symptoms, beliefs about medicine, and viewing HIV as a potential threat predicted better DOT adherence.

Burgess, J. L., Griffin, S., Jung, A. M., Hu, C., & Bui, D. P. (2018). Use of telematics data to identify driving behaviors associated with emergency service vehicle crashes. AAP.
Best, B., Burchette, S., Li, H., Stek, A., Hu, C. -., Wang, J., Hawkins, E., Byroads, M., Watts, H., Smith, E., Fletcher, C. V., Mirochnick, M., Capparelli, E. V., & IMPAACT P1026S Protocol Team, . (2015). Pharmacokinetics of Tenofovir during Pregnancy and Postpartum. HIV Medicine.